60 Degrees Pharmaceuticals Shares Are Trading Higher After the Company Announced Ethics Approval of an Open Label, Expanded Access Study of the ARAKODA Regimen of Tafenoquine in Combination With Standard of Care Regimens in Immunosuppressed Patients...
60 Degrees Pharmaceuticals Shares Are Trading Higher After the Company Announced Ethics Approval of an Open Label, Expanded Access Study of the ARAKODA Regimen of Tafenoquine in Combination With Standard of Care Regimens in Immunosuppressed Patients...
60度藥品股票交易較高，因爲公司宣佈在免疫抑制患者群體中獲得了ARA KODA方案替硫莫昔齊治療的標準板擴展研究的倫理批准......
60 Degrees Pharmaceuticals Shares Are Trading Higher After the Company Announced Ethics Approval of an Open Label, Expanded Access Study of the ARAKODA Regimen of Tafenoquine in Combination With Standard of Care Regimens in Immunosuppressed Patients With Persistent/relapsing Babesiosis
藥品公司60 Degrees Pharmaceuticals宣佈該公司的ARAKODA方案和標準療法方案相結合，擴大開放標籤研究以治療免疫抑制患者的持續/複發性瘧疾，並獲得道德批准，其股票價格上漲。
熱門討論
中概股財報季火熱：驚喜盈利能否延續漲勢？
1. 哪些行業可能成為本輪財報季的市場焦點？ 2. 在政府強調科技創新和可持續發展的背景下，你認為哪些行業具有最大的增長潜力？
Moomoo News Global
03/04 23:26
中國兩會：會議前後股票價格變動的關鍵要點